GSK, CureVac forge ahead with mid-stage plans for flu, Covid mRNA vaccines
GSK-partnered mRNA biotech CureVac released interim Phase I data on its new mRNA vaccines for Covid and the flu, causing its stock $CVAC to jump 25%.
While the data are early and mainly address the safety of the new vaccines, CureVac CEO Franz-Werner Haas told Endpoints News that releasing the interim data was the biotech’s way of saying, “Yes, we are back in the race.”
CureVac’s first attempt at an mRNA vaccine flamed out after it failed its pivotal trial, which CureVac attributed in part to the rise of new variants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.